Skip to main content

Grace Therapeutics, Inc.

GRCE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001444192

In the last 90 days, Grace Therapeutics, Inc. insiders filed 4 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.74M in total; no superinvestor holds it.

13F holders, Q2 2023

Institutional positions in Grace Therapeutics, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
11
−1 vs. Q1 2023
Shares held
389.5K
−21.1K (−5.1%) vs. Q1 2023
Total value
$204.2K
+$14.6K (+7.7%) vs. Q1 2023
New holders
2
0 more added
Sold out
3
2 more reduced

Compare with Q1 2023: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting GRCE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2023: 11 institutions
Q1 2021: 0 institutionsQ2 2021: 0 institutionsQ3 2021: 14 institutionsQ4 2021: 13 institutionsQ1 2022: 9 institutionsQ2 2022: 10 institutionsQ3 2022: 9 institutionsQ4 2022: 9 institutionsQ1 2023: 12 institutionsQ2 2023: 11 institutionsQ3 2023: 12 institutionsQ4 2023: 9 institutionsQ1 2024: 10 institutionsQ2 2024: 12 institutionsQ3 2024: 12 institutionsQ4 2024: 15 institutionsQ1 2025: 17 institutionsQ2 2025: 20 institutionsQ3 2025: 20 institutionsQ4 2025: 23 institutionsQ1 2026: 34 institutionsQ2 2026: 33 institutions
Value heldQ2 2023: $204.2K
Q1 2021: $0Q2 2021: $0Q3 2021: $356.5KQ4 2021: $248.8KQ1 2022: $183.7KQ2 2022: $108.2KQ3 2022: $53.1KQ4 2022: $24.8KQ1 2023: $189.6KQ2 2023: $204.2KQ3 2023: $1.55MQ4 2023: $1.65MQ1 2024: $4.34MQ2 2024: $6.30MQ3 2024: $6.36MQ4 2024: $7.84MQ1 2025: $9.17MQ2 2025: $11.3MQ3 2025: $11.0MQ4 2025: $15.0MQ1 2026: $19.7MQ2 2026: $8.74M
Institutions holding GRCE and their total value by quarter
QuarterHoldersValue
Q2 202633$8.74M
Q1 202634$19.7M
Q4 202523$15.0M
Q3 202520$11.0M
Q2 202520$11.3M
Q1 202517$9.17M
Q4 202415$7.84M
Q3 202412$6.36M
Q2 202412$6.30M
Q1 202410$4.34M
Q4 20239$1.65M
Q3 202312$1.55M
Q2 202311$204.2K
Q1 202312$189.6K
Q4 20229$24.8K
Q3 20229$53.1K
Q2 202210$108.2K
Q1 20229$183.7K
Q4 202113$248.8K
Q3 202114$356.5K
Q2 20210$0
Q1 20210$0

Institutions, Q2 2023

Shares, value and share of portfolio for each institution holding Grace Therapeutics, Inc.; share changes are against Q1 2023.

Institutions holding GRCE in Q2 2023
InstitutionSharesValue% of portfolioChange in sharesAction
TD Private Client Wealth LLC240,797$126.4K0.01%00.0%Unchanged
Renaissance Technologies LLC67,600$35.0K0.00%−23,168−25.5%Reduced
National Bank of Canada18,418$9.66K0.00%00.0%Unchanged
Geode Capital Management, LLC18,348$9.63K0.00%00.0%Unchanged
Two Sigma Securities, LLC15,087$7.92K0.00%+15,087New
Jane Street Group, LLC14,216$7.46K0.00%+14,216New
Morgan Stanley11,295$5.93K0.00%00.0%Unchanged
Royal Bank of Canada3,510$2.00K0.00%00.0%Unchanged
Federation des caisses Desjardins du Quebec179$940.00%−6−3.2%Reduced
ICA Group Wealth Management, LLC57$290.00%00.0%Unchanged
TD Waterhouse Canada Inc.4$30.00%00.0%Unchanged
Virtu Financial LLC0$00.00%−22,254−100.0%Sold out
UBS Group AG0$00.00%−3,744−100.0%Sold out
JPMorgan Chase & Co0$00.00%−1,250−100.0%Sold out